These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 34523055)

  • 1. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphoma: Standard of Care After the PETAL Study?
    Gisselbrecht C
    J Clin Oncol; 2018 Sep; ():JCO1800498. PubMed ID: 30222483
    [No Abstract]   [Full Text] [Related]  

  • 2. Defining and treating high-grade B-cell lymphoma, NOS.
    Olszewski AJ; Kurt H; Evens AM
    Blood; 2022 Sep; 140(9):943-954. PubMed ID: 34525177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on the Classification of and Diagnostic Approaches to Mature T-Cell Lymphomas.
    Zhang X; Zhou J; Han X; Wang E; Zhang L
    Arch Pathol Lab Med; 2022 Aug; 146(8):947-952. PubMed ID: 34524423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Reduced Image Noise on Deauville Scores in Patients with Lymphoma Scanned on a Long-Axial Field-of-View PET/CT-Scanner.
    Korsholm K; Overbeck N; Dias AH; Loft A; Andersen FL; Fischer BM
    Diagnostics (Basel); 2023 Mar; 13(5):. PubMed ID: 36900090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma.
    Yang DH; Jung SH; Ahn JS; Kim YK; Min JJ; Bom HS; Lee JJ; Kim HJ
    Chonnam Med J; 2015 Dec; 51(3):109-14. PubMed ID: 26730361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG-PET for Early Response Assessment in Lymphomas: Part 2-Diffuse Large B-Cell Lymphoma, Use of Quantitative PET Evaluation.
    Cheson BD; Kostakoglu L
    Oncology (Williston Park); 2017 Jan; 31(1):71-76. PubMed ID: 28090627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma.
    Kurch L; Dührsen U; Hüttmann A; Georgi TW; Sabri O; Kluge R; Hasenclever D
    EJNMMI Res; 2021 Sep; 11(1):90. PubMed ID: 34523055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Only strongly enhanced residual FDG uptake in early response PET (Deauville 5 or qPET ≥ 2) is prognostic in pediatric Hodgkin lymphoma: Results of the GPOH-HD2002 trial.
    Kurch L; Hasenclever D; Kluge R; Georgi T; Tchavdarova L; Golombeck M; Sabri O; Eggert A; Brenner W; Sykora KW; Bengel FM; Rossig C; Körholz D; Schäfers M; Feuchtinger T; Bartenstein P; Ammann RA; Krause T; Urban C; Aigner R; Gattenlöhner S; Klapper W; Mauz-Körholz C
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27539. PubMed ID: 30426671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma.
    Hasenclever D; Kurch L; Mauz-Körholz C; Elsner A; Georgi T; Wallace H; Landman-Parker J; Moryl-Bujakowska A; Cepelová M; Karlén J; Álvarez Fernández-Teijeiro A; Attarbaschi A; Fosså A; Pears J; Hraskova A; Bergsträsser E; Beishuizen A; Uyttebroeck A; Schomerus E; Sabri O; Körholz D; Kluge R
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1301-8. PubMed ID: 24604592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trial.
    Schmitz C; Rekowski J; Müller SP; Hertenstein B; Franzius C; Ganser A; Bengel FM; Kroschinsky F; Kotzerke J; La Rosée P; Freesmeyer M; Hoeffkes HG; Hertel A; Behringer D; Mesters R; Weckesser M; Mahlmann S; Haberkorn U; Martens U; Prange-Krex G; Brenner W; Giagounidis A; Moeller R; Runde V; Sandmann M; Hautzel H; Wilop S; Krohn T; Dürk H; Heike M; Alashkar F; Brinkmann M; Trenn G; Wacker D; Kreisel-Büstgens C; Bernhard H; Heil G; Larisch R; Kurch L; Jöckel KH; Hoelzer D; Klapper W; Boellaard R; Dührsen U; Hüttmann A
    Hematol Oncol; 2020 Aug; 38(3):244-256. PubMed ID: 32067259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial.
    Georgi TW; Kurch L; Hasenclever D; Warbey VS; Pike L; Radford J; Sabri O; Kluge R; Barrington SF
    PLoS One; 2020; 15(4):e0231027. PubMed ID: 32240248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
    Schmitz N; Truemper L; Bouabdallah K; Ziepert M; Leclerc M; Cartron G; Jaccard A; Reimer P; Wagner E; Wilhelm M; Sanhes L; Lamy T; de Leval L; Rosenwald A; Roussel M; Kroschinsky F; Lindemann W; Dreger P; Viardot A; Milpied N; Gisselbrecht C; Wulf G; Gyan E; Gaulard P; Bay JO; Glass B; Poeschel V; Damaj G; Sibon D; Delmer A; Bilger K; Banos A; Haenel M; Dreyling M; Metzner B; Keller U; Braulke F; Friedrichs B; Nickelsen M; Altmann B; Tournilhac O
    Blood; 2021 May; 137(19):2646-2656. PubMed ID: 33512419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim PET in Diffuse Large B-Cell Lymphoma.
    Kurch L; Hüttmann A; Georgi TW; Rekowski J; Sabri O; Schmitz C; Kluge R; Dührsen U; Hasenclever D
    J Nucl Med; 2021 Aug; 62(8):1068-1074. PubMed ID: 33246974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease.
    Kluge R; Wittig T; Georgi TW; Kurch L; Sabri O; Wallace WH; Klekawka T; Fernández-Teijeiro A; Ceppi F; Karlén J; Pears J; Cepelová M; Fosså A; Beishuizen A; Hjalgrim LL; Körholz D; Mauz-Körholz C; Hasenclever D
    J Nucl Med; 2021 Mar; 62(3):338-341. PubMed ID: 32764122
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.